A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes

Trial Profile

A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms GEM-CARBO
  • Most Recent Events

    • 19 Mar 2014 Accruel to date is 14% according to UK Clinical Research Network record.
    • 09 Mar 2009 Status changed from recruiting to active, no longer recruiting, according to United Kingdom Clinical Research Network.
    • 01 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top